Relmada Therapeutics, Inc.
RLMD Nasdaq
SEC CIK 1553643
Follow Relmada Therapeutics
Weekly email: filings, results
Net income
−$13.9M
−37.4% vs same quarter last year
EPS, diluted
−$0.12
+60% vs same quarter last year
Operating cash flow
−$12.6M
−87.2% vs same quarter last year
Operating income
−$13.1M
−26.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | $0 |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | −$157M |
| FY21 | −$125.8M |
| FY20 | −$59.5M |
| FY19 | −$17.3M |
| FY18 | −$9M |
| FY17 | −$6.3M |
| FY16 | −$3M |
| FY15 | −$20.8M |
| FY14 | - |
| FY13 | −$19.9M |
| FY12 | −$6.9M |
| FY11 | −$874K |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | −$209.9M |
| FY19 | −$95.3M |
| FY18 | −$6M |
| FY17 | −$6.5M |
| FY16 | −$13.7M |
| FY15 | −$16.3M |
| FY14 | - |
| FY13 | −$2.2M |
| FY12 | - |
| FY11 | - |